Autobahn Therapeutics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2017-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.autobahntx.com
Study of ABX-002 for the Adjunctive Treatment of Depressive Episodes Associated With Bipolar Depression in Adults
- First Posted Date
- 2025-03-25
- Last Posted Date
- 2025-03-26
- Lead Sponsor
- Autobahn Therapeutics, Inc.
- Target Recruit Count
- 35
- Registration Number
- NCT06869187
- Locations
- 🇺🇸
Autobahn Site #201, Cromwell, Connecticut, United States
🇺🇸Autobahn Site #208, Cherry Hill, New Jersey, United States
🇺🇸Autobahn Site #205, Marlton, New Jersey, United States
Study of ABX-002 for the Adjunctive Treatment of Major Depressive Disorder (AMPLIFY)
- First Posted Date
- 2024-10-09
- Last Posted Date
- 2025-02-14
- Lead Sponsor
- Autobahn Therapeutics, Inc.
- Target Recruit Count
- 230
- Registration Number
- NCT06633016
- Locations
- 🇺🇸
Autobahn Site #132, Chandler, Arizona, United States
🇺🇸Autobahn Site #116, Phoenix, Arizona, United States
🇺🇸Autobahn Site #140, Long Beach, California, United States
SAD/MAD of ABX-002-1902 Investigating the Safety, Pharmacokinetics/Pharmacodynamics of in Healthy Subjects
- First Posted Date
- 2022-09-06
- Last Posted Date
- 2023-09-15
- Lead Sponsor
- Autobahn Therapeutics, Inc.
- Target Recruit Count
- 48
- Registration Number
- NCT05528315
- Locations
- 🇦🇺
Nucleus Network, Melbourne, Victoria, Australia
© Copyright 2025. All Rights Reserved by MedPath